162 related articles for article (PubMed ID: 36435710)
1. Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
Alsyouf M; Ladi-Seyedian SS; Konety B; Pohar K; Holzbeierlein JM; Kates M; Willard B; Taylor JM; Liao JC; Kaimakliotis HZ; Porten SP; Steinberg GD; Tyson MD; Lotan Y; Daneshmand S;
Urol Oncol; 2023 Feb; 41(2):109.e9-109.e14. PubMed ID: 36435710
[TBL] [Abstract][Full Text] [Related]
2. Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-Risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?
Tadrist A; Gondran-Tellier B; McManus R; Al Balushi K; Akiki A; Gaillet S; Delaporte V; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
J Endourol; 2021 Jul; 35(7):1042-1046. PubMed ID: 33626963
[No Abstract] [Full Text] [Related]
3. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review.
Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
BJU Int; 2022 Dec; 130(6):730-740. PubMed ID: 35238145
[TBL] [Abstract][Full Text] [Related]
4. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
[TBL] [Abstract][Full Text] [Related]
6. Early Photodynamic Diagnosis Cystoscopy After Bacillus Calmette-Guérin (BCG) Induction for High-Risk Nonmuscle Invasive Bladder Cancer Significantly Increased the Detection of BCG Refractory Tumors.
Morelli M; Baboudjian M; Vanacore D; Gondran-Tellier B; McManus R; Karsenty G; Lechevallier E; Montanari E; Boissier R
J Endourol; 2021 Dec; 35(12):1824-1828. PubMed ID: 34107773
[No Abstract] [Full Text] [Related]
7. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
[No Abstract] [Full Text] [Related]
8. Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.
Yuk HD; Kim JK; Jeong CW; Kwak C; Kim HH; Ku JH
Biomed Res Int; 2018; 2018():9432606. PubMed ID: 30271788
[TBL] [Abstract][Full Text] [Related]
9. 'Real-life experience': recurrence rate at 3 years with Hexvix
Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
[TBL] [Abstract][Full Text] [Related]
10. Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results.
de la Rosette J; Martov A; Hurle R; Favre G; Mamoulakis C; Castanheira de Oliveira M; Stenzl A; Linares-Espinós E; Trelles Guzmán CR; Gravas S; Knoll T; Boz MY; Herrmann T; Laguna P
World J Urol; 2022 Mar; 40(3):727-738. PubMed ID: 34741631
[TBL] [Abstract][Full Text] [Related]
11. Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Nishimura N; Miyake M; Nakahama T; Miyamoto T; Nishimoto K; Oyama M; Matsushita Y; Miyake H; Fukuhara H; Inoue K; Kobayashi K; Matsumoto H; Matsuyama H; Fujii T; Hirao Y; Fujimoto K
Int J Urol; 2023 Dec; 30(12):1112-1119. PubMed ID: 37605814
[TBL] [Abstract][Full Text] [Related]
12. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer.
Zapała P; Dybowski B; Poletajew S; Białek Ł; Niewczas A; Radziszewski P
World J Surg Oncol; 2018 Jan; 16(1):6. PubMed ID: 29334958
[TBL] [Abstract][Full Text] [Related]
13. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
[TBL] [Abstract][Full Text] [Related]
15. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
Matsushita Y; Miyake M; Nishimura N; Nishimoto K; Fukuhara H; Kobayashi K; Oyama M; Inoue K; Matsuyama H; Fujimoto K; Miyake H
Int J Clin Oncol; 2024 Feb; 29(2):205-212. PubMed ID: 38112832
[TBL] [Abstract][Full Text] [Related]
17. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013776. PubMed ID: 34850382
[TBL] [Abstract][Full Text] [Related]
18. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
19. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
[TBL] [Abstract][Full Text] [Related]
20. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
